Skip to content
The Policy VaultThe Policy Vault

Calquence (acalabrutinib) — Highmark

Mantle Cell Lymphoma (MCL)

Initial criteria

  • age ≥ 18 years
  • diagnosis of MCL (ICD-10 C83.1)
  • EITHER received at least one prior therapy OR (ineligible for autologous HSCT AND use in combination with bendamustine and rituximab)